Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: Mixed treatment comparison using placebo as common comparator

摘要

I would like to thank you for showing interest in our work. We have reviewed the letter you wrote to us in response to our latest article entitled "An indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator" which was published in the Journal of Clinical Rheumatology and available on line from 21 June 2011.As was stated in the original article, all the studies included in the Mixed Treatment Comparison (MTC)-based analysis had ACR20 as a primary endpoint. It is under this pretext that the study of Mease et al. published by The Lancet was excluded [1], The study of Mease et al. employed a PsARC score as opposed to a primary endpoint of ACR20. We acknowledge that a mistake occurred within our references that may have caused confusion. However, from the data presented in Table 2, it is clear that these scores were obtained from the impact 2 study conducted by Antoni et al. [2, 3]. We are aware that the protocol's design gave us the opportunity of switching from one type of therapy to another after a 16-week period. We, however, chose to continue using the data from the impact 2 study for a further 8 weeks.